<DOC>
	<DOCNO>NCT00814216</DOCNO>
	<brief_summary>This study aim study efficacy ( measure change FEV1 ) safety two-week administration oral QAV680 treatment patient asthma. `</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics QAV680 Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : Mild moderate persistent asthma least 6 month . Exclusion criterion : Past recent history significant medical illness and/or lab abnormality include limited ECG abnormality , abnormal LFT , HIV , Hep B/C , Allergic disorder , pancreatic disease , serious underlie respiratory disease , life threaten asthma , renal disease etc Surgical and/or medical condition significantly effect ADME drug . Prior use asthma medication ( except SABA 's ) prior 2 week dose Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>QAV680</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>asthma</keyword>
</DOC>